Assembly Biosciences (ASMB) Registration Filing summary

Company overview and business model

• Focuses on developing innovative therapeutics for serious viral diseases, with a pipeline including clinical-stage therapies for herpes, hepatitis delta, hepatitis B, and transplant-related herpesviruses.

• Business strategy centers on advancing next-generation antivirals in areas of high unmet need and significant market opportunities, with near-term clinical readouts anticipated for several programs in 2025.

• Collaboration with Gilead Sciences provides expertise in virology and a partner for late-stage development and commercialization.

• Operates from South San Francisco, California, with a research team experienced in bringing over 15 antiviral drugs to market.

Financial performance and metrics

• Financial statements for the year ended December 31, 2024, audited by Ernst & Young LLP, are incorporated by reference.

• Common stock last traded at $10.85 per share on March 19, 2025, on Nasdaq Global Select Market.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including operations financing, potential debt repayment, and possible business acquisitions.